ClinicalTrials.gg
CompletedNCT04488601PEARLUpdated Jan 24, 2024

Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study

A Phase 2 interventional study of Rapamycin and Placebo in Aging, sponsored by AgelessRx. Completed at 1 site in United States. Open to participants aged 50 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-24.

Sponsored by AgelessRx · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 10 months ago, and no results have been posted to the registry.
  • Registered 6 months after the study started (first participant enrolled Jan 2020, registered Jul 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Study summary

This is a randomized, placebo-controlled trial into the safety and efficacy in reducing clinical measures of aging in an older adult population.

Read the detailed description

A randomized, double-blind, placebo-controlled trial assessing the effects of low and high doses of intermittent Rapamycin on a weekly schedule. The researchers aim to establish a long-term safety profile, determine the long-term efficacy of Rapamycin in reducing clinical aging measures, and biochemical and physiological endpoints associated with declining health and aging in healthy older adults.

02

Conditions studied

  • Aging

Keywords

  • rapamycin
  • aging
  • longevity
  • sirolimus
  • healthy aging
  • age-related conditions
03

In context

Lead sponsor

AgelessRx is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50-85
  • Any sex
  • Any ethnicity
  • Interest in taking Rapamycin off-label
  • Willing to undergo tests
  • Relatively good health with only well-managed chronic diseases (hypertension, coronary artery disease, type II diabetes, etc.) clinically stable
  • Adequate cognitive function to be able to give
  • Technologically competent to complete web forms and perform video calls with the PI

Exclusion criteria

Exclusion Criteria:

  • Anemia - Hg \< 9.0 g/dl, Leukopenia - white blood cells (WBC) \< 3,500/mm3 , Neutropenia - \< 2,000/mm3 , or count - platelet count \< 125,000/mm3
  • Premenopausal females (due to menstruation-induced anemia, etc.)
  • Patients scheduled to undergo major surgery in the next 12 months
  • Patients undergoing or scheduled to undergo chemotherapy or any other treatment for
  • Patients scheduled for therapy for transplant
  • Patients with impaired wound healing or history of a chronic open wound
  • Untreated dyslipidemia with LDL-c > 190 and family history of dyslipidemia, Total cholesterol > 350 mg/dl, or triglycerides > 880 mg/dl.
  • Impaired hepatic function, including elevated alkaline Phosphatase levels, (AST), alanine aminotransferase (ALT), Albumin, or T. Bili.
  • /AIDS, chronic Lyme, Babesia, Ehrlichiosis, Anaplasmosis, or other chronic infections that require ongoing treatment or monitoring
  • Allergy to Rapamycin
  • Any form of primary or secondary immune dysfunction or deficiency (e.g. X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID))
  • Chronic oral or immunosuppressive medication use (e.g. Enbrel, Humira, methotrexate).
  • Fibromyalgia or Chronic Fatigue Syndrome/Myalgic Encephalomyelitis, Breast Implant Illness,
  • Congestive heart failure: self-assessed functional status of heart failure (NYHA) classification III or IV
  • Impaired renal function, as defined as (GFR) \< 30
  • Poorly controlled diabetes, as defined as > 7%
  • Type I Diabetes, or Insulin-dependent Type II diabetes
  • Substance abuse disorder either untreated or if treated within the last 5 years
  • PTSD, Bipolar disorder, Schizophrenia, or any other untreated or poorly controlled mental health or mood disorder, or history of hospitalization due to mental health condition
  • Those who have taken metformin, rapamycin, or rapalogs in the past 6 months

    • (volunteers who were on metformin for aging can participate, provided they agree to stop taking metformin before and during the trial)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Rapamycin 5

    Rapamycin 5 mg/week

    Drug: Rapamycin

  • Experimental
    Rapamycin 10

    Rapamycin 10 mg/week

    Drug: Rapamycin

  • Placebo comparator
    Placebo 1

    Placebo once per week

    Drug: Placebo

Interventions

  • Rapamycin in 2 different dosage forms.

    Also known as: Sirolimus, Rapamune, Rapacan, Siromus, Raparen, Rapasim, Sirova

  • DrugPlacebo

    Placebo capsules

06

What researchers measure

Primary outcomes

  1. Changes in visceral fat as measured by dual-energy x-ray absorptiometry (DXA) scan

    Visceral fat changes from baseline as determined by DXA scan.

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

Secondary outcomes

  1. bone density

    Changes in bone density from baseline as determined by DXA scan

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

  2. lean body mass

    Changes in lean body mass from baseline as determined by DXA scan

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

  3. adverse events

    Number of patients with adverse events using standard AE reporting (FDA regulations 21CFR314.80 and 1CFR213.32(s))

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

  4. complete blood count (CBC)

    changes in CBC from baseline

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

  5. Change of blood electrolytes(serum potassium, sodium, chloride, and carbon dioxide in mmol/L)measured at baseline and after 6 and 12 months.

    Difference in the change of blood electrolytes(serum potassium, sodium, chloride, and carbon dioxide in mmol/L) compared with the baseline at 6 and 12 months between the intervention and control group is to be analyzed.

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

  6. Change of liver function as measured by serum globulin in g/dL, measured at baseline and after 6 and 12 months.

    Difference in the change of liver function as measured by serum globulin in g/dL compared with the baseline at 6 and 12 months between the intervention and control group is to be analyzed.

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

  7. Change of liver function as measured by serum bilirubin in mg/dL, measured at baseline and after 6 and 12 months.

    Difference in the change of liver function as measured by serum bilirubin in mg/dL compared with the baseline at 6 and 12 months between the intervention and control group is to be analyzed.

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

  8. Change of liver function as measured by serum alkaline phosphatase, AST, and ALT in IU/L, measured at baseline and after 6 and 12 months.

    Difference in the change of liver function as measured by serum alkaline phosphatase, AST, and ALT in IU/L compared with the baseline at 6 and 12 months between the intervention and control group is to be analyzed.

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

  9. Change of renal function as measured by serum albumin in g/dL, measured at baseline and after 6 and 12 months.

    Difference in the change of renal function as measured by serum albumin in g/dL compared with the baseline at 6 and 12 months between the intervention and control group is to be analyzed.

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

  10. Change of renal function as measured by serum creatinine and uric acid in mg/dL, measured at baseline and after 6 and 12 months.

    Difference in the change of renal function as measured by serum creatinine and uric acid in mg/dL compared with the baseline at 6 and 12 months between the intervention and control group is to be analyzed.

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

  11. Change in lipids (serum total cholesterol, triglycerides, HDL, and LDL cholesterol in mg/dL) measured at baseline and after 6 and 12 months.

    Difference in the change of lipids(serum total cholesterol, triglycerides, HDL and LDL cholesterol in mg/dL) compared with the baseline at 6 and 12 months between the intervention and control group is to be analyzed.

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

  12. Change in fasting serum glucose in mg/dL, measured at baseline and after 6 and 12 months.

    Difference in the change of fasting serum glucose in mg/dL compared with baseline at 6 and 12 months between the intervention and control group is to be analyzed.

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

  13. Change in insulin in uIU/mL, measured at baseline and after 6 and 12 months.

    Difference in the change of fasting serum insulin in uIU/mL compared with baseline at 6 and 12 months between the intervention and control group is to be analyzed.

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

  14. Change in fasting serum IGF-1 in ng/mL, measured at baseline and after 6 and 12 months.

    Difference in the change of fasting serum IGF-1 in ng/mL compared with baseline at 6 and 12 months between the intervention and control group is to be analyzed.

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

  15. Change in serum Hemoglobin A1c in % of total hemoglobin, measured at baseline and after 6 and 12 months.

    Difference in the change of serum Hemoglobin A1c in % of total hemoglobin compared with baseline at 6 and 12 months between the intervention and control group is to be analyzed.

    Time frame: 6 month interim analysis of the data, 12 month safety profile will be established

07

Study locations

1 site
  • AgelessRx
    Chicago, Illinois 60605, United States
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: as soon as available

Access criteria: Institutional review board (IRB) approval or at the discretion of PI/sponsor

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Dec 2023, 47 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2020
First posted
Jul 28, 2020
StartActual
Jan 1, 2020
Primary completionActual
Dec 30, 2023
CompletionActual
Dec 30, 2023
Last update
Jan 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04488601
Lead sponsor
AgelessRx
Responsible party
Sponsor
First posted
Jul 28, 2020
Start date
Jan 1, 2020
Primary completion
Dec 30, 2023
Completion
Dec 30, 2023
Last update
Jan 24, 2024

Study contacts

James Watson, MD
principal investigator · University of California, Los Angeles
Sajad Zalzala, MD
study director · AgelessRx

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion